A growing body of evidence has shown significantly prolonged progression-free survival and a manageable toxicity profile for first-line CDK4/6 inhibitor plus AI in patients with hormone receptor-positive/HER2-negative advanced breast cancer [31, 32]. The gene discussed is CDK4; the disease is breast carcinoma.